← Back to Home

A New Option for HER2-Positive Breast Cancer Maintenance Therapy: FDA Approves Tukysa Three-Drug Combination

After initial treatment brings the disease under control, adding tucatinib may extend the time advanced breast cancer remains without progression. But a higher rate of adverse events also makes identifying which patients need intensified treatment a key question.

By SURL BioNews

For patients with advanced breast cancer, once initial treatment stabilizes the disease, the next challenge is how to sustain that period of stability. On October 7, the U.S. Food and Drug Administration (FDA) approved adding the oral drug tucatinib (brand name Tukysa) to two antibody therapies for maintenance treatment of HER2-positive breast cancer, providing a new option for delaying disease progression while also introducing a trade-off between efficacy and treatment burden.

The approval applies to adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy. The new combination consists of tucatinib, trastuzumab, and pertuzumab; tucatinib is a HER2-targeted tyrosine kinase inhibitor. The FDA-recommended dose is 300 milligrams twice daily, used with the two antibodies until disease progression or unacceptable toxicity.

The approval was based on HER2CLIMB-05, a phase 3 randomized, double-blind, placebo-controlled trial involving 654 participants. Participants first received four to eight cycles of trastuzumab, pertuzumab, and taxane chemotherapy and entered the maintenance treatment comparison only if investigators determined that their disease had not progressed. The trial allowed patients with or without brain metastases to participate; those with hormone receptor-positive disease could also continue endocrine therapy.

With both groups receiving dual-antibody therapy, median progression-free survival was 24.9 months in the group receiving added tucatinib and 16.3 months in the group receiving added placebo, a difference of 8.6 months. The hazard ratio for disease progression or death was 0.64, indicating that the new combination reduced the risk of these events during the trial's follow-up period. This is a statistical comparison between the two groups and cannot be interpreted to mean that every patient gains the same amount of additional time.

Whether delaying progression also extends life remains uncertain: overall survival data were still immature at the time of this progression-free survival analysis. Although the trial included patients with brain metastases and its secondary endpoints included central nervous system progression-free survival, the primary results for the overall patient population alone cannot establish that patients with all types of brain metastases derive the same degree of benefit.

More intensive treatment also brought more adverse events. According to trial data summarized by OncLive, 42.3% of patients in the tucatinib group experienced grade 3 or higher treatment-emergent adverse events, compared with 24.4% in the control group. Rates of grade 3 or higher elevations in the liver enzyme ALT were 13.5% and 0.6%, respectively, while rates of grade 3 or higher diarrhea were 6.1% and 4.0%. The FDA announcement also stated that the drug's labeling includes a boxed warning for hepatotoxicity, along with warnings about risks such as diarrhea.

The next question raised by the new approval is therefore how to identify those who most need intensified treatment. In an OncLive interview, Mayo Clinic oncologist Ciara O’Sullivan noted that some patients can maintain good disease control over the long term with dual-antibody therapy alone, combined with endocrine therapy depending on hormone receptor status. Clinical practice still needs better biomarkers to distinguish these patients from those who require more intensive treatment. The three-drug combination expands maintenance treatment options, while determining how much benefit an individual patient may gain and how much burden they may bear requires more nuanced judgment.

References

  1. FDA
  2. The ASCO Post
  3. OncLive